Palmowski, Andriko
Boyadzhieva, Zhivana
Nielsen, Sabrina M.
Muche, Burkhard
Hermann, Sandra
Boers, Maarten
Bliddal, Henning
Christensen, Robin
Wiebe, Edgar
Buttgereit, Frank
Funding for this research was provided by:
Elsbeth Bonhoff Stiftung (228, 228, 228, 228, 228, 228)
Abbvie, Amgen, Almirall, Biogen, BMS, Chugai, Galapagos, Generic Assays, GSK, Hexal, Horizon Therapeutics, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche and Sanofi
The Oak Foundation (OCAY-18-774-OFIL, OCAY-18-774-OFIL, OCAY-18-774-OFIL, OCAY-18-774-OFIL)
Charité - Universitätsmedizin Berlin
Article History
Received: 15 March 2023
Accepted: 2 June 2023
First Online: 7 June 2023
Declarations
:
: The Rh-GIOP cohort study has received a positive vote from the local ethics committee (EA1/367/14) and is registered with clinicaltrials.gov (NCT02719314). All participants had to give their written consent to participate.
: All authors agreed for this manuscript to be sent for peer-review.
: AP, RC, SMN, SH, and ZB have no relevant conflicts of interest. EW reports consultancy fees, honoraria and travel expenses from Medac and Novartis. BM received consulting and speaker honoraria / congress support from UCB Pharma Germany, Amgen Germany, Stadapharm. FB reported receiving consultancy fees, honoraria and travel expenses from Abbvie, Horizon Therapeutics, and Pfizer, and grant support from Horizon Therapeutics. MB. consultancy fees from Novartis, speaker fees from Pfizer.